Latest News and Press Releases

- Three ASGCT abstracts highlight new data related to application of gene circuit technology to enhance efficacy and safety of cancer-killing CAR-NK cells - - ISCT abstract describes scalable,...

SOUTH SAN FRANCISCO, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that co-founders Tim Lu, MD, PhD, Chief...

- Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors - - CAR-NK cells armed with calibrated...

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced the acceptance of an abstract for presentation at the American Association...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and...

- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common...

- Preclinical data demonstrates complete functionality of SENTI-202 OR+NOT Logic Gated gene circuits for the elimination of AML cancer cells while sparing healthy stem cells - - Presentation...

- SENTI-401 engineered to target colorectal cancer cells while sparing healthy cells - - Preclinical proof-of-concept data suggest that Logic Gated gene circuits can be used in CAR-NK cells to...

- Preclinical data demonstrates functionality of SENTI-202 OR/NOT Logic Gated gene circuits for the elimination of AML cells while sparing healthy cells - - SENTI-202 is one of several pipeline...

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced that its co-founder and chief executive officer, Tim Lu, MD, PhD, has been...